Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Christopher C. Butler et al.
Summary: The use of azithromycin does not show significant benefits in reducing recovery time or risk of hospitalization for people with suspected COVID-19 in the community. This finding underscores the importance of prudent antibiotic use during the pandemic, as increased antibiotic use can lead to antimicrobial resistance.
LANCET (2021)
Article
Medicine, General & Internal
COVID-19, community trials, and inclusion
Paramjit S Gill et al.
LANCET (2021)
Share Paper
